



Division of Pulmonary, Critical Care and Sleep Medicine

WTC respiratory disease findings in the WTC EHC "Survivor" population

Joan Reibman, MD

Professor of Medicine and Environmental Medicine

New York University School of Medicine

Medical Director, NYU/Bellevue Asthma Airways Environment Program

Medical Director, H+H WTC Environmental Health Center

Funding

- WTC cooperative agreements
 - #200-2011-39413 Evaluation of Distal Airway Injury Following Exposure to World Trade Center Dust
 - U01 OH011317 (Small airway COPD in the Survivor population)
 - U01OH010404 (Uncontrolled Lower respiratory Symptoms in WTC Survivor population)
- Clinical Center: 1E11OH0030(2008 2011) 200-2011-39391C(previous), 200-2017-93427(current)
- Data Center: 200-2011-39379C(previous) 200-2017-93327 (current)





Goals

- What have we learned about lower respiratory symptoms in community members
 - Respiratory symptoms after 9/11 and exposure
 - Location of lung injury
 - Mechanisms of LRS
- Implications for other exposures/illnesses
- What have we learned and what do we need next







Local workers/office workers,residents commuters, teachers, students

Acute exposures

Dust clouds

The cloud in Lower Manhattan, south of Chambers Street.



Chronic indoor and outdoor exposures from resuspended dust and fumes Local workers returned to work September 17, 2001




Document respiratory symptoms in the community



WTC Residents Respiratory Health Study

- NYS DOH, local community, NYU
- Funded by CDC
- Cross-sectional study of "exposed" and "control" residential population
- Designed, implemented and completed 16 months after 9/11/01
- One of few studies with a control population





New-onset respiratory symptoms increased in previously normal exposed residents

Symptom, %	Exposed (n=2410)	Control (n=271)	Crude Incidence ratio (95% CI)*
Cough	16.0	4.0	4.0 (2.2-7.4)
Shortness of breath (SOB)	10.6	3.6	2.9 (1.5-5.7)
Wheeze	10.5	1.6	6.5 (2.4-17.3)
Chest tightness	8.4	1.6	5.2 (2.0-13.9)
Exertional dyspnea	7.4	1.7	4.5 (1.7-11.9)
Any of the above	26.4	7.5	3.5 (2.3-5.5)

^{*b*}Symptom frequency \geq 2 days per week in the past 4 weeks.

* Effect still statistically significant after adjusting for age, gender, education, smoking and race.



Reibman et al., Environ Health Perspectives 113: 406;2005 NYU Langone

Increase in medical consultation and asthma medicine use in previously normal residents

	Exposed (n=2410)	Control (n=271)	Crude IR (95% CI)*
Unplanned Medical Visits (in the past 12 months), %	13.7	7.8	1.8 (1.2-2.7)*
Fast Relief Med Use (in the past 4 weeks)	8.0	3.3	2.4 (1.3-4.7)*
Controller Med Use (in the past 4 weeks)	8.6	3.7	2.3 (1.3-4.3)*

No diagnosis of asthma, chronic obstructive pulmonary disease, chronic bronchitis, or other lung disease before 9/11/2001.

* Effect still statistically significant after adjusting for age, gender, education, and race.



Lin S. et al., Amer J Epidemiol 162:499;2005



Onset of LRS in community confirmed by NYC DOH WTC Health Registry

- NYC Department of Health WTC Registry
- 71,437 participants exposed individuals
- Survey initiated in 2003, repeated measures
- Adverse health effects in community
 - Brackbill et al. MMMWR Surveill Summ 2006;55:1-18
 - Farfel et al. J Urban Health 2008;85:880-909





WTC Environmental Health Center

- WTC EHC pilot program at Bellevue Hospital
- Philanthropic funds, City funds, Federal funds in 2008
- "WTC EHC Survivor program" 2011 James Zadroga
 9/11 Health and Compensation Act
 - Highly regulated and monitored programs under the CDC/NIOSH
 - Provide treatment for "Certified Conditions" for symptomatic "Survivors" (community members)
 - Certified conditions include aerodigestive disorders, mental health diagnoses, cancers






Characteristics of patients in the WTC EHC differ from responders

1005(53)
<mark>893(47)</mark>
48 ± 12
867(46)
318(17)
217(11)
792(42)
1178(62)
709(37)
378(20)
566(30)
749(40)

Reibman et al. J Occup Environ Med. 2009



Aerodigestive symptoms in previously normal WTC EHC population are similar to those in responders




NYC HEALTH+ HOSPITALS

Reibman et al. J Occup Environ Med. 2009



Aerodigestive symptoms remain most common Certified WTC-related conditions in WTC EHC



Both acute and chronic exposures associated with lower respiratory symptoms

TABLE 4—Composite Exposure Scales Following September 11, 2001, and Their Association With Case Status Among New York World Trade Center-Area Residents and Workers

		All Participants (n = 785)			Residents	^d (n = 479)		Area Workers ^d (n = 422)	
Composite Exposure Scale and Component Variables	α^{a}	OR ^b (95% CI)	AOR ^c (95% CI)	α_{a}	OR ^b (95% CI)	AOR ^c (95% CI)	α_{a}	OR ^b (95% CI)	AOR ^c (95% CI)
			Acute Expos	ure					
Dust cloud: density	0.95	1.9 (1.6, 2.3)	1.7 (1.3, 2.2)	0.96	1.9 (1.5, 2.4)	1.5 (1.1, 2.1)	0.94	2.1 (1.7, 2.7)	1.8 (1.2, 2.7)
Personal appearance after thickest part of cloud									
Visibility in thickest part of cloud									
Time first caught, relative to World Trade									
Center collapses									
Dust cloud: time	0.93	1.3 (1.1, 1.5)	1.0 (0.8, 1.4)	0.92	1.3 (1.1, 1.5)	1.0 (0.7, 1.3)	0.93	1.2 (1.0, 1.5)	1.1 (0.8, 1.7)
Duration of time in dust cloud									
Proportion of time in thickest part of cloud									
			Chronic Expo	sure					
Dust: home/workplace	0.92	1.7 (1.4, 2.0)	2.1 (1.5, 2.8)	0.89	1.6 (1.3, 2.0)	1.8 (1.2, 2.8)	0.94	1.8 (1.4, 2.2)	2.6 (1.7, 4.2)
Extent of dust coverage at home or workplace									
Depth of thickest dust layer at home or workplace									
Proportion of home or workplace most affected									
Smoke: home/workplace	0.92	1.3 (1.1, 1.5)	1.8 (1.3, 2.6)	0.86	1.3 (1.0, 1.6)	1.5 (0.9, 2.4)	0.95	1.3 (1.0, 1.5)	2.5 (1.4, 4.2)
Smelled smoke inside, outside, both									
Duration of time during which smelled smoke									
Time: home/workplace	0.85	0.9 (0.8, 1.0)	1.2 (0.9, 1.6)	0.82	0.8 (0.7, 1.0)	0.9 (0.6, 1.3)	0.86	1.0 (0.8, 1.2)	1.4 (0.9, 2.3)
Time at home or workplace									
Month first at home or workplace after 9/11									
Cleaning: home/workplace	0.94	1.6 (1.4, 1.9)	1.0 (0.7, 1.3)	0.92	1.7 (1.4, 2.1)	1.3 (0.9, 1.9)	0.97	1.6 (1.3, 2.0)	0.8 (0.5, 1.3)
Participated in cleaning of home or workplace									
Number of items cleaned by participant ^a									
Time spent cleaning home									

Note. AOR = adjusted odds ratio; CI = confidence interval; OR = odds ratio.

Maslow et al. Amer J Public Health 102: 1186, 2012



What have we learned about inhalation injury from WTC dust/fumes in Survivor population

Location of injury



Particulate matter (PM) - Physical properties

- PM10 aerodynamic diameter <10 μm
- PM2.5 aerodynamic diameter \leq 2.5 μ m
- Ultrafine PM aerodynamic diameter <0.1 μm_{\odot}
- Size influences site of damage in the airway
- Large particles expected to cause upper airway[®] damage, smaller can traverse to lower airways





Physical properties of WTC dust

- 1.2 million tons of building materials
- 90% of settled particles >10 □m diameter
- 11,000 tons of particles < 2.5 □m diameter
- Acute exposures from massive dust from dust clouds
- Chronic exposures from resuspended dust, indoor resuspended dust
- Dust composed of large and small particles





Acute pneumonia in a firefighter after WTC exposure






Rom et al. Am J Respir Crit Care Med 2002



Mineralogic analysis of bronchoalveolar lavage from firefighter



(A) Amosite asbestos fiber (uncoated)

(B) Fly ash particle


(C) Degraded fibrous glass.

- Environmental particles in the lung
- Large particles deep in the lung

Rom et al. Am J Respir Crit Care Med 2002



Pathologic findings in community member with WTC exposure – persistent particles in lung



D

Ε

Scanning electron microscopy with energy dispersive x-ray spectroscopy (SEM-EDS) revealed silica, AlSi, Ti, Talc, Metals (steel, copper, chromium) YC EALTH+ OSPITALS Caplan-Shaw et al. J Occup Environ Med. 53: 981, 2011



Location of injury

- In massive exposures, large particles able to access deep in lung
- Large and small particles persisted in the lung





Location of injury

- In massive exposures, large particles able to access deep in lung
- Large and small particles persisted in the lung
- Location of damage? Was there small airway/distal lung involvement associated with lower respiratory symptoms





Lung function studies used to detect airway injury

- Spirometry standard measure of lung function
- May not detect small airway abnormalities
- Forced oscillation techniques (impulse oscillometry) can detect subtle changes in airway function not identified by spirometry
- Did patients with lower respiratory symptoms have small airway abnormalities





Are LRS symptoms associated with small airway involvement not detected by spirometry?

- Routine measurements of forced oscillation in patients in the WTC EHC
- Most patients with normal spirometry had abnormal FOT measurements
- Couldn't interpret <u>without a control population</u>






Collaboration with the NYC DOH WTC Registry: Case-Control Study

- DOH WTC Registry
- Field study of WTC Registry participants
- Symptomatic Cases lower respiratory symptoms at repeated surveys
- Controls no symptoms at any survey
- Compared lung function (spirometry and FOT) between Symptomatic Cases and Controls






Most cases and controls had normal spirometry



Symptomatic cases had abnormal small airway function (FOT)



Friedman et al. Amer J Resp Crit Care Med 2011



Abnormal small airway function associated with severity of LRS in patients with normal spirometry

	Total Resistance R_5 (cmH ₂ O/L/s)		Small Airway Function R ₅₋₂₀ (cmH ₂ O/L/s)		
	median	IQR	median	IQR	
Wheeze Severity					
None (n = 384)	4.38	2.04	0.71	0.83	
Mild (n = 97)	4.32	2.22	0.82	0.79	
Moderate $(n = 80)$	4.66	2.36	0.80	0.90	
Severe $(n = 50)$	5.06	1.95	0.99	1.03	
p value [*]	NS		0.03		
Wheeze frequency					
(days/wk)					
0-1 (n = 400)	4.41	2.10	0.72	0.90	
2-6 (n = 129)	4.46	2.20	0.79	0.70	
7 (n = 70)	5.02	2.70	1.02	1.20	
p value [*]	NS		0.05		

Berger et al. ERJ Open Res 2015; 1:00043-2015

NYC

HOSPITAI S



Small airway injury

- Small airway abnormalities detected in symptomatic WTC EHC patients even with normal screening spirometry
- Small airway abnormalities associated with exposure (data not shown)
- Small airway abnormalities associated with severity LRS
- First use of FOT (IOS) to assess environmental injury in the lung
- Too for future use for environmental exposures





Mechanisms for WTC lower respiratory symptoms?






Mechanisms of asthma are complex

Many stimuli

Heterogeneous pathways


Redundant pathways

No all asthma is the same






Type 2 inflammation in asthma






Inflammation in response to environmental stimuli



Acute pneumonia in a firefighter






Rom et al. Am J Respir Crit Care Med 2002



Acute eosinophilic pneumonia in a firefighter







Rom et al. Am J Respir Crit Care Med 2002



Peripheral eosinophils associated with wheeze and airway obstruction


Catagony	High Eos	Low Eos		
Category	N = 176	N = 964	OR^{\dagger}	P value
Spirometry pattern, n (%)				
Normal	117 (66)	735 (76)	1	
Obstructed ^a	27 (16)	70 (7)	2.42	0.0002
Low FVC ^b	32 (18)	159 (17)	1.27	NS

Kazeros et al. J Asthma. 2013; 1:25-32





Inflammation in response to environmental stimuli



Lower respiratory symptoms associated with systemic inflammation C-reactive protein

• Symptomatic patients in WTC EHC (n = 754)

TABLE 3. Association of LRS With High CRP Level*				
Symptom†	OR	P Value		
Cough (<i>n</i> = 704)	1.83	0.001		
Wheezing $(n = 690)$	1.73	0.008		
Dyspnea at rest $(n = 729)$	1.67	0.008		
Chest tightness $(n = 698)$	1.61	0.011		

*Adjustment includes sex, Age, log (BMI), smoking status, caught in WTC dust cloud, and exposure category.

†The number varies for each symptom because of missing data. OR, odds ratio.



Kazeros et al, J. Occ Environ Med 2013



Abnormal FVC and small airway measures associated with systemic inflammation - CRP

Spirometry pattern, n(%)	High CRP	Low CRP	OR*	P value
Normal	161(30)	367(70)	1	
Obstructed ^a	22(29)	54(71)	1.39	0.28
Low FVC ^b	65(52)	59(48)	2.58	<0.001
Low FVC/Obstruct ed ^c	13(50)	13(50)	1.99	0.13

- Elevated CRP associated with low FVC
- Elevated CRP associated with abnormal small airway measures (FOT) (data not shown)





C-reactive protein associated with +PTSD score

Table 3

Multiple linear regressions of PTSD, anxiety and depression scores; n = 641.

	PTSD		Anxiety		Depression ^a	
	β (SE) ^b	P value	β (SE)	P value	β (SE)	P value
log(CRP)	1.12 (0.43)	0.01	0.19 (0.18)	0.27	0.55 (0.29)	0.06
Demographics						
Gender - male	-2.49 (1.25)	0.05	-0.95(0.51)	0.06	-1.87 (0.84)	0.03
Age at first visit	-0.07(0.06)	0.26	-0.02(0.02)	0.40	-0.07~(0.04)	0.06
Race/ethnicity Hispanic	4.73 (1.53)	0.00	1.73 (0.62)	0.01	2.31 (1.03)	0.03
Education \leq High School	0.23 (1.5)	0.88	0.35 (0.61)	0.57	-0.08 (1.0)	0.93
Income \leq \$30k/year	3.72 (1.36)	0.01	1.82 (0.55)	0.00	2.62 (0.91)	0.00
log(BMI)	-3.57 (3.4)	0.29	-1.56 (1.38)	0.26	-2.28(2.28)	0.32
Ever smoker	0.37 (1.54)	0.81	-0.62(0.63)	0.33	0.06 (1.03)	0.95
Exposures						
WTC dust cloud exposure	5.01 (1.3)	0.00	1.39 (0.53)	0.01	1.98 (0.87)	0.02
Exposure classification						
Resident	-2.19 (1.72)	0.20	0.12 (0.70)	0.87	0.60 (1.15)	0.60
Clean-up worker	1.48 (2.16)	0.49	2.41 (0.88)	0.01	2.06 (1.44)	0.15
Other	-2.92 (2.0)	0.14	-0.49(0.81)	0.55	-0.94(1.34)	0.48
Lower respiratory symptoms						
Cough	0.47 (1.4)	0.74	0.52 (0.57)	0.37	0.87 (0.94)	0.35
Wheeze	0.71 (1.38)	0.61	0.38 (0.56)	0.50	0.41 (0.92)	0.66
Dyspnea at rest	3.05 (1.37)	0.03	1.73 (0.56)	0.00	1.87 (0.92)	0.04
Chest tightness	4.70 (1.37)	0.00	2.61 (0.56)	0.00	2.79 (0.92)	0.00

Significant P-values are bolded.

a 5 participants missing depression data: n = 636 for depression analysis.

^b β , regression coefficient; (SE), standard error.



Rosen et al. J. Psychiatric Res 2017



C-reactive protein associated with PTSD clusters

Table 4

Multiple linear regressions of PTSD symptom cluster scores; n = 641.

	Re-experiencing	l I	Avoidance		Negative cognitions/mood		Arousal	
	β (SE) ^a	P value	β (SE)	P value	β (SE)	P value	β (SE)	P value
log(CRP)	0.08 (0.03)	0.002	0.08 (0.04)	0.02	0.06 (0.03)	0,06	0.05 (0.03)	0.08
Demographics								
Gender - male	-0.13 (0.08)	0.09	-0.35 (0.10)	0.001	-0.07 (0.08)	0.42	-0.16 (0.09)	0.07
Age at first visit	0.00 (0.00)	0.78	0.00 (0.00)	0.41	-0.01 (0.00)	0.16	0.00 (0.00)	0.24
Race/ethnicity Hispanic	0.25 (0.10)	0.008	0.30 (0.13)	0.02	0.21 (0.10)	0.04	0.36 (0.11)	0.001
Education \leq High school	0.04 (0.09)	0.67	-0.03 (0.13)	0.80	-0.04 (0.10)	0.68	0.06(0.11)	0.58
Income≤ \$30k/year	0.29 (0.08)	0.001	0.34 (0.11)	0,003	0.19 (0.09)	0.04	0.13 (0.10)	0,17
log(BMI)	-0.11 (0.21)	0.62	-0.52 (0.28)	0.07	-0.19 (0.23)	0.41	-0.21 (0.24)	0.39
Ever smoker	-0.08 (0.10)	0.40	-0.04 (0.13)	0.76	0.08 (0.10)	0.47	0.09 (0.11)	0.39
Exposures								
WTC dust cloud	0.30 (0.08)	0.00	0.34 (0.11)	0,002	0,25 (0.09)	0.005	0.32 (0.09)	0.001
Exposure classification								
Resident	-0.16(0.11)	0.13	-0.28 (0.14)	0.05	-0.06 (0.12)	0.60	-0.11 (0.12)	0.39
Clean-up worker	0.02 (0.13)	0.89	0.06 (0.18)	0,74	0.17 (0.15)	0.23	0.08 (0.15)	0.61
Other	-0.17 (0.12)	0,16	-0.25 (0.17)	0.14	-0.19 (0.13)	0.17	-0.12 (0.14)	0.38
Lower respiratory sympton	15							
Cough	0.01 (0.09)	0.88	-0.03 (0.12)	0.80	0.05 (0.09)	0.57	0.04 (0.10)	0,70
Wheeze	-0.01 (0.09)	0,89	0.08 (0.12)	0,50	0.04 (0.09)	0.66	0.08 (0.10)	0.42
Dyspnea at rest	0.20 (0.08)	0.02	0.21 (0.11)	0.07	0.17 (0.09)	0.06	0.15 (0.10)	0.13
Chest tightness	0.30 (0.08)	0.00	0.19 (0.11)	0.09	0,24 (0.09)	0.01	0.33 (0.10)	0.001

Significant P-values are bolded.

ALS Wision Name or Footer

NYC

HEALTH-

^a β, regression coefficient; (SE), standard error.

Rosen et al. J. Psychiatric Res 2017



Mechanisms

- Multiple types of inflammation associated with LRS
 - Classic T2 inflammation (eosinophils)
 - Non eosinophilic inflammation
- Different types of inflammation associated with different patterns of lung function
- Systemic inflammatory marker (CRP) associated with both LRS and mental health symptoms





		FVC		FEV ₁	
	No.	Estimate	95% CI	Estimate	95% CI
Exposure category ^d					
Local worker	438	28**	(13.0, 43.0)	24.6***	(12.3, 36.8)
Resident	172	59.5***	(31.3, 87.7)	44.5***	(25.4, 63.5)
Rescue/recovery	67	122.8***	(86.1, 159.6)	80.4***	(52.3, 108.5)
Clean-up worker	247	61.3***	(46.3, 76.3)	36.3***	(24.2, 48.4)


- Improvement in lung function
- Least improvement in local workers
- Patients with abnormal lung function at baseline, did not become normal

Linear mixed effects model, adjusted, * p < 0.01, * p < 0.001, * p < 0.001, * p < 0.0001

TH+ Liu et al. J Occup Environ Med 2012



Many patients had persistence of lower respiratory symptoms at monitoring visits



Caplan-Shaw et al, AJIM 59; 777, 2016

HEALTH+

HOSPITALS



Uncontrolled lower respiratory study


- Adherence to high dose inhaled corticosteroids and long acting β_2 agonist (therapy for severe asthma) would improve LRS (controlled LRS) and
- Patients with uncontrolled lower respiratory symptoms (ULRS) have higher rates of abnormal large and small airway function and hyperresponsiveness compared with those with controlled LRS
- CDC/NIOSH -funded study





Uncontrolled lower respiratory study


- Recruit patients with LRS at initial visit, normal spirometry and uncontrolled LRS at monitoring
- Run-in for 3 months to confirm adherence to ICS/LABA
- Compare those with controlled LRS vs uncontrolled LRS:
 - airway hyperresponsiveness (methacholine)
 - vocal cord hyperresponsiveness paradoxical vocal cord movement (irritant exposure)





Adherence to ICS/LABA failed to improve LRS

- Few patients obtained controlled LRS
- Added patients with ULRS at initial visit, but controlled before enrollment into the study





Demographic and WTC exposure characteristics

	Total (n=73)	Uncontrolled (n = 54)	Controlled (n = 19)	p value
Age	55.6	55.3	56.2	0.62
Sex				
Female, n (%)	51 (70)	36 (67)	15 (79)	0.39
Male <i>,</i> n (%)	22 (30)	18 (33)	4 (21)	
BMI (SD)	30.3(7)	30.2(5)	30.8(6)	0.95
Exposure				
Dust cloud, n (%)	37 (51)	29 (53.7)	8 (42.1)	0.43





Large and small airway lung function

	Total (n=73)	Uncontrolled (n = 54)	Controlled (n = 19)	p value
FVC, % predicted FEV₁, % predicted FEV₁/FVC	93 (0.89) 90.9 (13.3) 76.5 (13.5)	90.1 (14.2)	94.1 (13.8) 93.6 (11) 79.4 (5.4)	
R5 R5-20	4.9 (1.6) 1.13 (1.02)	4.8 (1.5)	5.1 (2.1) 1.2 (1.5)	





Biomarkers of T2 inflammation not elevated

	Total (n=73)	Uncontrolled (n = 54)	Controlled (n = 19)	p value
FeNO (median, IQR) Eos > 300 cells/L, n (%)	17 (9.25) 12 (16.4)	18 (9.5) 11 (15.1)	14 (7.5) 1 (01.3)	0.05 0.2
Total IgE, kIU (median, IQR)	28.5 (63)	31 (74)	14 (7.5)	<0.0001





High rates of airway hyperresponsiveness (AHR)

	Total Uncontrolled Controlled p value				
	(n=73)	(n = 54)	(n = 19)		
AHR, n (%)* PVCM, n (%)	32 (54) 34 (51)	21 (49) 23 (47)	11 (69) 11 (61)	0.24 0.43	

*Completed by 59 ** Completed by 67





High rates of paradoxical vocal cord movement (PVCM)

	Total Uncontrolled Controlled p value				
	(n=73)	(n = 54)	(n = 19)		
AHR (%)* PVCM <i>,</i> n (%)	32 (54) 34 (51)	21 (49) 23 (47)	11 (69) 11 (61)	0.24 0.43	

*Completed by 59 ** Completed by 67





High rates of either +AHR or +PVCM

	Total U	p value		
	(n=73)	(n = 54)	(n = 19)	
AHR(%)*	32 (54)	21 (49)	11 (69)	0.24
PVCM <i>,</i> n (%)	34 (51)	23 (47)	11 (61)	0.43
+AHR or +PVCM	48 (77)			
*Completed by 59 ** Completed by 67				





Uncontrolled lower respiratory symptom study

- Most patients with persistent uncontrolled LRS had symptoms despite good adherence to high dose ICS/LABA
- High rates of AHR and PVCM despite therapy
- No difference in AHR or PVCM in those with controlled or uncontrolled LRS at time of study
- Few had evidence of type 2 inflammation (eosinophils, FeNO, IgE)





Future questions

- What are the underlying mechanisms for persistent LRS symptoms and hyperresponsiveness?
- Have pathways changed over time?
- Are inflammatory pathways involved in persistent LRS?
- Is there a role for persistent activation of irritant neural pathways?
- What is the role of systemic inflammation and interaction with comorbid conditions?





Future questions

- Need further studies to understand mechanisms for LRS
- Characterize heterogeneity among patients
- Biologic samples blood samples
 - initial samples to predict disease (no longer possible)
 - current samples for persistent symptoms
- Need clinical trials to identify appropriate therapy
- Need to understand interaction with comorbidities
- Continue longitudinal studies to identify those that improve vs those with persistent symptoms





Importance

- Improved understanding of mechanisms can promote improved treatment of WTC population
 - Target location i.e small or large airways target treatment
 - Target pathway of inflammation (precision medicine)
 - Target multiple co-morbid conditions or common pathways
- Study of WTC –related respiratory disease has/will provide information that can enhance our understanding of other environmental injury





Acknowledgements

WTC Residents Study

Linda Rogers, MD Shao Lin, PhD Syni-An Hwang, PhD James Bower Mridu Gulati, MD. Kenneth Berger MD Roberta Goldring, MD

Community organizations

WTC EHC Steering Committee Beyond Ground Zero Network 9/11 Environmental Action Battery Park Residents Coalition Independence Plaza Tenants Org Southbridge Tenants Org Biostatistics/Epi/Data Mengling Liu, PhD Yongzhao Shao, PhD Michael Marmor, PhD Qinyi Cheng Meng Qian Maria Elena Fernandez-Beros, PhD Guy Frazer

NYC DOHMH

Steven Friedman, MD Carey Maslow, PhD WTC Environmental Center **Roberta Goldring, MD** Ken Berger, MD Kymara Kyng RN Sybille Liautaud, MD Stephanie Lau MD Jaime Gonzalez, MD Sam Parsia, MD Caralee Caplan Shaw, MD Angeliki Kazeros, MD Meredith Turetz, MD Mohammed Gumman, MD Neel Choksy, MD William Rom, MD Waiwah Chung, RN Herman Yee, MD

<u>H+H</u>

Terry Miles Evelyn Zumba Scott Penn









Thank You